NCT06821958

Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Combined double immune checkpoint inhibition and radiofrequency electromagnetic field treatment for patients with advanced hepatocellular carcinoma

Detailed description

Charité University Medicine Berlin is currently the only German University Hospital with an available capacitive radiofrequency electromagnetic field treatment device. While there is retrospective data available regarding the assumed effectiveness and low toxicity profile of radiofrequency electromagnetic field treatment for various solid tumors including liver cancer, there is no prospective data available on the combined effect of first-line palliative double immune checkpoint inhibition and radiofrequency electromagnetic field treatment for patients with advanced hepatocellular carcinoma. The investigators aim to conduct a feasibility trial and plan to compare the results with data of a prospective trial with a comparable patient population who received double immune checkpoint inhibition alone.

Conditions

• Hepatocellular Carcinoma (HCC)

Interventions

Type	Name	Description
DEVICE	Radiofrequency electromagnetic field treatment	Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz

Timeline

• Start date: 2025-03-01
• Primary completion: 2026-06-15
• Completion: 2029-02-28
• First posted: 2025-02-12
• Last updated: 2025-02-12

Locations

1 site across 1 country: Germany